Table 3 Included studies which reported access to treatment defined as treatment receipt and utilisation (n = 15)
Author (year) | Outcome of interest | Type of SACT treatment | Main finding(s) |
|---|---|---|---|
Accordino et al. (2017) [26] | Receipt of EOL care which included receipt of IV chemotherapy within the last 14 days of life | IV chemotherapy as treatment within the last 14 days of life | 60% receipt of IV chemotherapy as treatment within the last 14 days of life |
Alves et al. (2022) [33] | Receipt of no SACT treatment | Unspecified SACT | 60% of women received no first-course treatment |
Cole et al. (2019) [34] | Receipt of specialist palliative care (SPC) which included non-curative systemic chemotherapy | Non-curative systemic chemotherapy | 18.5% received specialist palliative care (SPC) which included non-curative systemic chemotherapy |
Falchook et al. (2017) [35] | Receipt of chemotherapy within the last 14 days of life | Chemotherapy within the last 14 days of life | 14.1% received chemotherapy within the last 14 days of life |
Giap et al. (2023) [27] | Receipt of palliative care which included non-curative systemic therapy | Non-curative systemic chemotherapy | 21.4% received non-curative systemic chemotherapy |
Sathe et al. (2023) [28] | Receipt of cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors following secondary (metastatic) breast cancer diagnosis | Cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors | 76.3% received CDK4/6i |
Shih et al. (2009) [39] | Receipt of immunotherapy post diagnosis | Immunotherapy | 4% received immunotherapy post diagnosis |
Shiovitz et al. (2015) [40] | Utilisation of cancer-directed therapy which included chemotherapy | Chemotherapy | 61% received SACT |
Skinner et al. (2021) [32] | Receipt of systemic anticancer therapy | Unspecified SACT | 83% received SACT |
Small et al. (2012) [41] | Receipt of no first course anticancer therapy | Unspecified SACT—no first-course therapy | 12.8% received no first-course SACT therapy |
Statler et al. (2019) [30] | First-line treatment with chemotherapy and/or hormone therapy | First-line treatment with chemotherapy and/or hormone therapy | 60% received first-line treatment with hormone therapy, 39% received chemotherapy, and 42% of patients received anti-HER2 therapy |
Vyas et al. (2021) [5] | Receipt of initial systemic therapy within 6 months of secondary (metastatic) breast cancer diagnosis | Unspecified systemic anticancer therapy | 72.3% received initial (guideline concordant) systemic therapy within 6 months of secondary (metastatic) breast cancer diagnosis |
Wan & Jubelirer (2015) [35] | Receipt of chemotherapy within 6 months of diagnosis | Chemotherapy | 30.2% received chemotherapy |
Wang & Du (2015) [42] | Receipt of hormone therapy 1 year post initiation (stratified by chemotherapy use) | Hormone (endocrine) therapy | 70.8% received hormone therapy |
Wolfson et al. (2015) [43] | Receipt of care which included un specified SACT SACT at a National Cancer Institute Comprehensive Cancer Centre (NCI CCC) | Nonspecified SACT | **22–39 years 9.7% 40–65 years 90.3% |